Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years

Author:

Mela Aneta,Poniatowski Łukasz A.,Drop Bartłomiej,Furtak-Niczyporuk Marzena,Jaroszyński Janusz,Wrona Witold,Staniszewska Anna,Dąbrowski Jan,Czajka Anna,Jagielska Beata,Wojciechowska Monika,Niewada Maciej

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference28 articles.

1. Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry;Badora;J. Market Access Health Policy,2017

2. Cancer drugs: high price, uncertain value;Cohen;BMJ,2017

3. EY Poland Access to innovative cancer drugs in Poland in comparison with selected European Union countries and Switzerland

4. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications;Ferrario;Pharmacoeconomics,2017

5. Pricing of oral generic cancer medicines in 25 European countries; findings and implications;Godman;Generics Biosimilars Initiative J.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3